Copyright
©The Author(s) 2021.
World J Diabetes. Jul 15, 2021; 12(7): 1010-1025
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.1010
Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.1010
Characteristics by drug class | Glucocorticoids | 5-FU and analogs | PI3K/mTOR inhibitors | Immune checkpoint inhibitors |
Class effect on hyperglycemia | Yes | Yes | Yes | Negligible risk with the CTLA-4 inhibitor, ipililmumab |
Does occur with all PD-1 and PD-L1 inhibitors, most significantly when combined | ||||
Reversibility of hyperglycemia | Yes | No | Yes | No |
- Citation: Yim C, Mansell K, Hussein N, Arnason T. Current cancer therapies and their influence on glucose control. World J Diabetes 2021; 12(7): 1010-1025
- URL: https://www.wjgnet.com/1948-9358/full/v12/i7/1010.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i7.1010